"A randomized, double-blind Phase III study of copanlisib versus placebo in patients with rituximab-refractory indolent non-Hodgkin’s lymphoma (iNHL) – CHRONOS-2"

drug protocol number
BAY 80-6946 / 17322
drug sponsor
Bayer
drug study
BAY 80-6946/Copanlisib
drug trial site
KAUH-J
drug status
Terminated
drug phase